XML Financial LLC Sells 20,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

XML Financial LLC trimmed its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 66.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,000 shares of the biopharmaceutical company’s stock after selling 20,000 shares during the quarter. XML Financial LLC’s holdings in Catalyst Pharmaceuticals were worth $242,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $27,000. Park Square Financial Group LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $29,000. Farther Finance Advisors LLC grew its stake in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 1,495 shares during the last quarter. Sound Income Strategies LLC bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter worth $64,000. Finally, GAMMA Investing LLC grew its stake in shares of Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 579 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Trading Down 0.2%

Shares of NASDAQ CPRX opened at $22.07 on Wednesday. The firm’s 50-day moving average price is $23.91 and its 200-day moving average price is $22.90. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.75 and a 1-year high of $26.58. The firm has a market capitalization of $2.69 billion, a P/E ratio of 14.06, a P/E/G ratio of 0.90 and a beta of 0.72.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, June 5th. Robert W. Baird boosted their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Six equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average price target of $32.83.

Insider Activity

In other news, insider Gary Ingenito sold 44,000 shares of the company’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,627,468.99. This represents a 38.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Preethi Sundaram sold 1,600 shares of the company’s stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the transaction, the insider now owns 41,081 shares in the company, valued at $1,085,360.02. This represents a 3.75% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 247,924 shares of company stock worth $5,879,369. Company insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.